Animal models of stroke: Do they have value for discovering neuroprotective agents?

Trends in Pharmacological Sciences

Volumn 24, Issue 8, 2003, Pages 402-408

  Green, A Richard ^a   Odergren, Tomas ^b   Ashwood, Tim ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CHLORO 2 METHOXYPHENYL) 3 FLUORO 2,3 DIHYDRO 6 TRIFLUOROMETHYL 1H INDOL 2 ONE; 4 PHOSPHONOMETHYLPIPECOLIC ACID; ALTEPLASE; ANCROD; APTIGANEL; CALCIUM ANTAGONIST; CITICOLINE; CLOMETHIAZOLE; FIBRINOLYTIC AGENT; GAVESTINEL; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; LUBELUZOLE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALMEFENE; NIMODIPINE; PROUROKINASE;

BLOOD PRESSURE; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; COMPARATIVE STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HYPERGLYCEMIA; HYPOTHERMIA; NEUROPROTECTION; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION; REVIEW; RISK FACTOR; SEDATION; STROKE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0041659304     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00192-5     Document Type: Article

References (66)

1. Warlow C.P. Epidemiology of stroke. Lancet. 352:(Suppl. 3):1998;SIII1-SIII4.
2. Green A.R., Cross A.J. Neuroprotective Agents and Cerebral Ischaemia. 1997;Academic Press.
3. Wardlaw J.M., et al. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet. 350:1997;607-614.
4. Furlan A., et al. Intra-arterial prourokinase for acute ischemic stroke: the PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. J. Am. Med. Assoc. 282:1999;2003-2011.
5. Sherman D.G., et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomised controlled trial. Stroke treatment with ancrod trial. J. Am. Med. Assoc. 283:2000;2395-2403.
6. Ginsberg M.D. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection. The 2002 Thomas Willis Lecture. Stroke. 34:2003;214-223.
7. Kidwell C.S., et al. Trends in acute ischemic stroke trials through the 20th century. Stroke. 32:2001;1349-1359.
8. Green A.R. Why do neuroprotective drugs that are so promising in animals fail in the clinic? An industry perspective. Clin. Exp. Pharmacol. Physiol. 29:2002;1030-1034.
9. De Keyser J., et al. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci. 22:1999;535-540.
10. Gladstone D.J., et al. Toward wisdom from failure. Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke. 33:2002;2123-2136.
11. Green A.R., Cross A.J. Techniques for examining neuroprotective drugs in vivo. Int. Rev. Neurobiol. 40:1997;47-68.
12. Mohr J.P., et al. Middle cerebral artery. Barnett H.J.M., et al. Stroke: Pathophysiology, Diagnosis and Management. Vol. 1:1986;377-450 Churchill Livingstone.
13. Traystman R.J. Animal models of focal and global cerebral ischemia. ILAR J. 44:2003;85-95.
14. Brinker G., et al. Thrombolysis of cerebral clot embolism in rat: effect of treatment delay. NeuroReport. 10:1999;3269-3272.
15. Takano K., et al. Efficacy of intra-arterial and intravenous prourokinase in an embolic stroke model evaluated by diffusion-perfusion magnetic resonance imaging. Neurology. 50:1998;870-875.
16. Elger B., et al. MRI study on delayed ancrod therapy of focal cerebral ischaemia in rats. Eur. J. Pharmacol. 336:1997;7-14.
17. Sydserff S.G., et al. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br. J. Pharmacol. 135:2002;103-112.
18. Tissue plasminogen activator for acute ischemic stroke. New Engl. J. Med. 333:1995;1581-1587.
19. Broderick J.P., Hacke W. Treatment of acute ischemic stroke: Part 1 recanalization strategies. Circulation. 106:2002;1563-1569.
20. Lin B., et al. Hyperglycemic exacerbation of neuronal damage following forebrain ischemia: microglial, astrocytic and endothelial alterations. Acta Neuropathol. 96:1998;610-620.
21. Williams S.L., et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 59:2002;67-71.
22. Alvarez-Sabin J., et al. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke. 34:2003;1235-1241.
23. Parsons M.W., et al. Acute hyperglycemia adversely affects stroke outcome: A magnetic resonance imaging and spectroscopy study. Ann. Neurol. 52:2002;20-28.
24. Thornhill J., Corbett D. Therapeutic implications of hypothermic and hyperthermic temperature conditions in stroke patients. Can. J. Physiol. Pharmacol. 79:2001;254-261.
25. Schwab S., et al. Feasibility and safety of moderate hypothermia after massive hemispheric infarction. Stroke. 32:2001;2033-2035.
26. Wang Y., et al. Influence of admission body temperature on stroke mortality. Stroke. 31:2000;404-409.
27. Kammersgaard L.P., et al. Admission body temperature predicts long-term mortality after acute stroke. The Copenhagen Stroke Study. Stroke. 33:2002;1759-1762.
28. Castillo J., et al. Aggravation of acute ischemic stroke by hyperthermia is related to an excitotoxic mechanism. Cerebrovasc. Dis. 9:1999;22-27.
29. Horn J., et al. Nimodipine in animal model experiments of focal cerebral ischemia. A systematic review. Stroke. 32:2001;2433-2438.
30. Horn J., Limburg M. Calcium antagonists for ischemic stroke. A systematic review. Stroke. 32:2001;570-576.
31. Ahmed N., et al. Effect of intravenous nimodipine on blood pressure and outcome after acute stroke. Stroke. 31:2000;1250-1255.
32. Osborne K.A., et al. Quantitative assessment of early brain damage in a rat model of focal cerebral ischaemia. J. Neurol. Neurosurg. Psychiatry. 50:1987;402-410.
33. Wassmann H., et al. Nimodipine in experimental permanent focal cerebral ischemia. Zent. Bl. Neurochir. 53:1992;141-147.
34. Muir K.W., Lees K.R. Clinical experiences with excitatory amino acid antagonists. Stroke. 26:1995;503-513.
35. Dawson D.A., et al. A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke. Brain Res. 892:2001;344-350.
36. Lyden P., et al. Clomethiazole acute stroke study in ischemic stroke (CLASS-I). Final results. Stroke. 33:2002;122-128.
37. Sydserff S.G., et al. Clomethiazole is neuroprotective in models of global and focal cerebral ischaemia when infused at doses producing clinically relevant plasma concentrations. Brain Res. 862:2000;59-62.
38. Dirnagl N., et al. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22:1999;391-397.
39. Massieu L., et al. A comparative analysis of the neuroprotective properties of competitive and uncompetitive N-methyl-D-aspartate receptor antagonists in vivo: implications for the process of excitotoxic degeneration and its therapy. Neuroscience. 55:1993;883-892.
40. Baron J.C. Mapping the ischaemic penumbra with PET: implications for acute stroke treatment. Cerebrovasc. Dis. 9:1999;599-606.
41. Peeling J., et al. Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology. 40:2001;433-439.
42. Grotta A. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 33:2001;306-307.
43. Ringelstein E.B., et al. Type and extent of hemispheric brain infarctions and clinical outcome in early and delayed middle cerebral artery recanalization. Neurology. 42:1992;289-298.
44. Xue D., et al. Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke. 23:1992;894-899.
45. Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke. 32:2000;2257-2265.
46. Zhang Z., et al. A new rat model of thrombotic focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17:1997;123-135.
47. Yang Y.Y., et al. Neuroprotection by 2-h post-ischemia administration of two free radical scavengers, α-phenyl-N-tert-butyl nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischaemia. Exp. Neurol. 163:2000;39-45.
48. 3) reduces infarct volume following focal cerebral ischemia in spontaneously hypertensive rats, diabetic and non-diabetic Fisher 344 rats. Brain Res. 931:2002;68-73.
49. Hudzik T.J., et al. Long-term functional end points following middle cerebral artery occlusion in the rat. Pharmacol. Biochem. Behav. 65:2000;553-562.
50. Marshall J.W.B., et al. Comparison of the neuroprotective effect of clomethiazole, AR-R15896AR and NXY-059 in a primate model of stroke using histological and behavioural measures. Brain Res. 972:2003;119-126.
51. Recommendations for standards regarding pre-clinical neuroprotective and restorative drug development. Stroke. 30:1999;2752-2758.
52. Mackensen G.B., et al. Neuroprotection from delayed postischemic administration of a metalloporphyrin catalytic antioxidant. J. Neurosci. 21:2001;4582-4592.
53. Dewar D., et al. Drug development for stroke: importance of protecting cerebral white matter. Eur. J. Pharmacol. 375:1999;41-50.
54. Yam, P.S. et al. Topgraphical and quantative assessment of white matter injury following a focal ischaemic lesion in the rat brain. Brain Res. Protoc. 2, 315-322.
55. Dyker A.G., Lees K.R. Duration of neuroprotective treatment for ischemic stroke. Stroke. 29:1998;535-542.
56. Belayev L., et al. Human albumin therapy of acute ischemic stroke. Marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke. 32:2001;553-560.
57. Legos J.J., et al. Pharmacological interventions for stroke: failures and future. Expert Opin. Invest. Drugs. 11:2002;5603-5614.
58. Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 32:2001;1598-1606.
59. Davis S.M., et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke. 31:2000;347-354.
60. Clark W.M., et al. Cervene (Nalmefene) in acute ischemic stroke: final results of a phase III efficacy study. The Cervene Stroke Study Investigators. Stroke. 31:2000;1234-1239.
61. Diener H.S., et al. Lubeluzole in acute ischemic stroke treatment. A double-blind study with an 8-hour inclusion window comparing a 10-mg daily dose of lubeluzole with placebo. Stroke. 31:2000;2543-2551.
62. Sacco R.L., et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. J. Am. Med. Assoc. 285:2001;1719-1728.
63. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 57:2001;1428-1434.
64. Clarke W.M., et al. A phase III randomised efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology. 57:2001;1595-1602.
65. Albers G.W., et al. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. J. Am. Med. Assoc. 286:2001;2673-2682.
66. Fisher M., Bozik M.E. 90-Day outcome of patients receiving I.V. tPA in the POST trials. Stroke. 34:2003;283. (P145).